-
ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances
-
Maryland Woman Arrested in Decade-Long Cancer Scam Involving Fake Medical Team
-
Panthers Seek NFC South Lead Against Ravens as Baltimore Ends Skid
-
American Resources Corporation and ReElement Technologies Selected as Part of Winning U.S.-Led Consortium for Kenya's Strategic Mrima Hill Critical Minerals Project
-
Ryde Group Ltd Announces Non-Binding Term Sheet for Proposed Minority Investment in Multi Genius Limited and MOU on Technology Collaboration
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 20
-
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure
-
The DEA Laid The Trap - And State Marijuana Operators Took The Bait
-
5 Fun Date Night Ideas That Don't Cost a Fortune
-
Commonhold Explained: How New Leasehold Ban Changes Property Ownership in England and Wales
-
Factory Worker Dies in Rare Rectal Explosion Incident in Czechia
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Decoding UNFCCC Legal Language: The Hierarchy of Verbs in Climate Negotiations
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
Aytu BioPharma to Present at Upcoming October 2025 Conferences
DENVER, CO / ACCESS Newswire / October 10, 2025 / DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:
2025 Maxim Growth Summit
Date: October 22, 2025
Location: New York City
Investors should reach out to their Maxim sales representatives, or Robert Blum of Lytham Partners at [email protected] to schedule one-on-one meetings with Aytu's management.
Planet MicroCap Showcase: TORONTO 2025
Date: October 22, 2025 - October 23, 2025
Location: Toronto
Presentation Time: 2:30 p.m. Eastern time
Webcast: https://event.summitcast.com/view/34SFNFBix4cZpKNiohrXeh/eV26zB4GZpybjQPU4g6xja
If you would like to schedule one-on-one investor meetings with Aytu's management, and to attend the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub, please register here: REGISTER. Conversely, you can contact Robert Blum of Lytham Partners at [email protected] to assist in coordination.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
A.Anderson--AT